Clinical trials · New York, NY
Aggression clinical trials in New York
We’re tracking 15 recruiting aggression studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT05685173RecruitingPhase 1
Study safety of REGN5837 with odronextamab in adult B-cell lymphoma
This Phase 1 trial tests whether a new medicine (REGN5837) given with odronextamab is safe in adults with aggressive B-cell non-Hodgkin lymphoma. It may help researchers learn if this combination can work for patients whose disease has progressed after earlier treatments.
New York, New YorkAges 18 years+ - NCT05475925RecruitingPhase 1/Phase 2
Test drug DR-01 for specific blood cancer types
This early-phase study tests DR-01 to treat large granular lymphocytic leukemia (LGLL) or certain aggressive T-cell or cytotoxic lymphomas. It aims to see whether the drug is safe and can shrink or control the cancer.
New York, New YorkAges 18 years+ - NCT05826535RecruitingPhase 1/Phase 2
Test of CAR T-cell therapy for aggressive B-cell lymphoma
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
New York, New YorkAges 18 years+ - NCT05996185RecruitingPhase 2
Study of mogamulizumab plus chemotherapy for T-cell lymphoma
This trial is testing a drug called mogamulizumab combined with standard chemotherapy (DA-EPOCH or CHOEP) for people with aggressive T-cell lymphoma. It aims to see if the combination is safe and works better than chemotherapy alone.
New York, New YorkAges 18 years+ - NCT04996875RecruitingPhase 2
Bezuclastinib for advanced mast cell disease
This Phase 2 study tests bezuclastinib, a targeted medicine, in people with advanced systemic mastocytosis (including certain advanced forms with blood cancers). It aims to shrink measurable disease and improve symptoms, while helping people who may also need treatment for an associated blood cancer.
New York, New YorkAges 18 years+ - NCT06422806RecruitingPhase 3
Immunotherapy plus chemo for aggressive sarcoma
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
New York, New YorkAges 18 years+ - NCT05978141Recruiting
T-cell lymphoma registry study
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
New York, New YorkAges Any age - NCT07156565RecruitingPhase 1
Study of actinium therapy for advanced soft tissue sarcoma
This trial is testing a new type of radiation therapy for advanced soft tissue sarcoma that has not responded to other treatments. The goal is to see if this therapy can shrink tumors and help control the cancer.
New York, New YorkAges 18 years+ - NCT07434479Recruiting
Virtual reality mindfulness for aggression in schizophrenia
This study tests whether a virtual reality mindfulness program can help people with schizophrenia who have problems with impulsive aggression. You would use a VR headset for relaxation exercises and answer questions about your mood and behavior.
New York, New YorkAges 18–64 - NCT07091279RecruitingPhase 2
Test of Propranolol for Severe Behaviors in Autism
This study tests a medication called propranolol to see if it can reduce aggression and other severe behaviors in adolescents and adults with autism. It might be an option if you have frequent and serious challenging behaviors that other treatments haven't helped.
Staten Island, New YorkAges 12–40 - NCT06544265RecruitingPhase 1
SynKIR-310 for advanced B-cell lymphoma
This trial tests a new treatment called SynKIR-310 for people with B-cell non-Hodgkin lymphoma whose cancer has come back or not responded to at least 2 prior treatments. It may be an option if you've already had CAR T-cell therapy or cannot have it.
New Brunswick, New JerseyAges 18 years+ - NCT04045600Recruiting
Refining communication training for kids with behavior challenges
This study tests an improved version of functional communication training for children ages 3 to 17 whose destructive behavior (like hitting or yelling) happens often and is fueled by social attention. It aims to help children learn better ways to get attention instead of using hard-to-manage behaviors.
Somerset, New JerseyAges 3–17 - NCT05928247Recruiting
Behavior program for frequent challenging behaviors in children
This trial tests a structured (manualized) assessment and treatment approach for children who have very frequent challenging behaviors despite prior help. It aims to reduce these behaviors and improve daily functioning by targeting what keeps the behavior going.
Somerset, New JerseyAges 3–17 - NCT05537610Recruiting
Test a behavior strategy for frequent self-injury
This study looks at how to reduce serious problem behaviors (including self-injury) in children who have it many times per day even after previous treatment. It may help if your child’s behavior is driven by social attention or other positive effects and they can stay on the same supports, school plan, and medicines during the study.
Somerset, New JerseyAges 3–17 - NCT05925101Recruiting
Studying ways to reduce frequent behavior spikes in children
This study looks at basic and applied methods to understand “extinction bursts,” times when a hard-to-control behavior may briefly get worse before it improves. It may help families and clinicians choose safer, more effective behavior supports for children with very frequent problem behaviors.
Somerset, New JerseyAges 3–17
Hear when a new Aggression trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Where these studies are running near New York
Institutions with a site for the recruiting aggression studies listed above.
- Children's Specialized Hospital-Rutgers University Center for Autism Research, Education, and Services · 3 studies
- Memorial Sloan Kettering Cancer Center · 3 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 2 studies
- Memorial Sloan Kettering Nassau · 2 studies
- Montefiore Medical Center · 2 studies
- NYU Langone Health · 2 studies
- Rutgers Cancer Institute of New Jersey · 2 studies
- Center for Autism and the Developing Brain
What taking part in a aggression study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting aggression studies in New York.
Common questions
- Are there aggression clinical trials near New York?
- Yes. We're currently tracking 15 recruiting aggression studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a aggression study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a aggression trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New aggression studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.